• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

聚乙二醇化 SLN 作为一种有前途的方法，用于将吉非替尼递送至肺癌的淋巴系统。

PEGylated SLN as a Promising Approach for Lymphatic Delivery of Gefitinib to Lung Cancer.

机构信息

Kayyali Chair for Pharmaceutical Industry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.

Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.

出版信息

Int J Nanomedicine. 2022 Jul 28;17:3287-3311. doi: 10.2147/IJN.S365974. eCollection 2022.

DOI:10.2147/IJN.S365974
PMID:35924261
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9342893/
Abstract

PURPOSE

The present study aimed to develop gefitinib-loaded solid lipid nanoparticles (GEF-SLN), and GEF-loaded PEGylated SLN (GEF-P-SLN) for targeting metastatic lung cancer through the lymphatic system.

METHODS

The prepared SLNs were characterized in terms of physicochemical properties, entrapment efficiency, and in-vitro release. Furthermore, ex-vivo permeability was investigated using the rabbit intestine. Cytotoxicity and apoptotic effects were studied against A549 cell lines as a model for lung cancer.

RESULTS

The present results revealed that the particle size and polydispersity index of the prepared formulations range from 114 to 310 nm and 0.066 to 0.350, respectively, with negative zeta-potential (-14 to -27.6). Additionally, SLN and P-SLN showed remarkable entrapment efficiency above 89% and exhibited sustained-release profiles. The permeability study showed that GEF-SLN and GEF-P-SLN enhanced the permeability of GEF by 1.71 and 2.64-fold, respectively, compared with GEF suspension. Cytotoxicity showed that IC of pure GEF was 3.5 μg/mL, which decreased to 1.95 and 1.8 μg/mL for GEF-SLN and GEF-P-SLN, respectively. Finally, the apoptotic study revealed that GEF-P-SLN decreased the number of living cells from 49.47 to 3.43 when compared with pure GEF.

CONCLUSION

These results concluded that GEF-P-SLN is a promising approach to improving the therapeutic outcomes of GEF in the treatment of metastatic lung cancer.

摘要

目的

本研究旨在通过淋巴系统开发用于治疗转移性肺癌的吉非替尼载药固体脂质纳米粒（GEF-SLN）和载药聚乙二醇化固体脂质纳米粒（GEF-P-SLN）。

方法

对制备的 SLN 进行物理化学性质、包封效率和体外释放度的表征。此外，还使用兔肠进行了体外通透性研究。针对肺癌模型 A549 细胞系，研究了细胞毒性和凋亡作用。

结果

结果表明，所制备的制剂的粒径和多分散指数范围分别为 114nm 至 310nm 和 0.066 至 0.350，且具有负的 Zeta 电位（-14 至-27.6mV）。此外，SLN 和 P-SLN 表现出超过 89%的显著包封效率，并表现出持续释放的特征。通透性研究表明，与 GEF 混悬液相比，GEF-SLN 和 GEF-P-SLN 分别使 GEF 的通透性增强了 1.71 倍和 2.64 倍。细胞毒性显示，纯 GEF 的 IC 为 3.5μg/mL，而 GEF-SLN 和 GEF-P-SLN 分别降低至 1.95μg/mL 和 1.8μg/mL。最后，凋亡研究表明，与纯 GEF 相比，GEF-P-SLN 将活细胞数量从 49.47%降低至 3.43%。

结论

这些结果表明，GEF-P-SLN 是一种有前途的方法，可以提高 GEF 在治疗转移性肺癌中的治疗效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9895/9342893/0c801d69e328/IJN-17-3287-g0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9895/9342893/1ef3932cd293/IJN-17-3287-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9895/9342893/b6a57bb59dfd/IJN-17-3287-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9895/9342893/88c0562f172c/IJN-17-3287-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9895/9342893/13d1ddc4d24c/IJN-17-3287-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9895/9342893/11d3f1ebc7db/IJN-17-3287-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9895/9342893/b8e87a011761/IJN-17-3287-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9895/9342893/cb7415a2863b/IJN-17-3287-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9895/9342893/34e5d6987177/IJN-17-3287-g0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9895/9342893/4588302d750a/IJN-17-3287-g0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9895/9342893/f86c56ac5f2f/IJN-17-3287-g0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9895/9342893/1f5d49d830fb/IJN-17-3287-g0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9895/9342893/0c801d69e328/IJN-17-3287-g0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9895/9342893/1ef3932cd293/IJN-17-3287-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9895/9342893/b6a57bb59dfd/IJN-17-3287-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9895/9342893/88c0562f172c/IJN-17-3287-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9895/9342893/13d1ddc4d24c/IJN-17-3287-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9895/9342893/11d3f1ebc7db/IJN-17-3287-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9895/9342893/b8e87a011761/IJN-17-3287-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9895/9342893/cb7415a2863b/IJN-17-3287-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9895/9342893/34e5d6987177/IJN-17-3287-g0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9895/9342893/4588302d750a/IJN-17-3287-g0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9895/9342893/f86c56ac5f2f/IJN-17-3287-g0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9895/9342893/1f5d49d830fb/IJN-17-3287-g0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9895/9342893/0c801d69e328/IJN-17-3287-g0012.jpg

相似文献

1
PEGylated SLN as a Promising Approach for Lymphatic Delivery of Gefitinib to Lung Cancer.聚乙二醇化 SLN 作为一种有前途的方法，用于将吉非替尼递送至肺癌的淋巴系统。
Int J Nanomedicine. 2022 Jul 28;17:3287-3311. doi: 10.2147/IJN.S365974. eCollection 2022.
2
Engineered Nanoscale Lipid-Based Formulation as Potential Enhancer of Gefitinib Lymphatic Delivery: Cytotoxicity and Apoptotic Studies Against the A549 Cell Line.工程化的纳米级脂质基制剂作为吉非替尼淋巴递药的潜在增强剂：对 A549 细胞系的细胞毒性和凋亡研究。
AAPS PharmSciTech. 2022 Jul 1;23(6):183. doi: 10.1208/s12249-022-02332-7.
3
Optimization of Gefitinib-Loaded Nanostructured Lipid Carrier as a Biomedical Tool in the Treatment of Metastatic Lung Cancer.优化载吉非替尼的纳米结构脂质载体作为治疗转移性肺癌的生物医学工具。
Molecules. 2023 Jan 3;28(1):448. doi: 10.3390/molecules28010448.
4
TPGS decorated NLC shift gefitinib from portal absorption into lymphatic delivery: Intracellular trafficking, biodistribution and bioavailability studies.TPGS修饰的纳米脂质载体将吉非替尼从门静脉吸收转变为淋巴输送：细胞内转运、生物分布及生物利用度研究。
Colloids Surf B Biointerfaces. 2023 Mar;223:113148. doi: 10.1016/j.colsurfb.2023.113148. Epub 2023 Jan 21.
5
Co-Delivery Anticancer Drug Nanoparticles for Synergistic Therapy Against Lung Cancer Cells.载抗癌药物纳米粒子协同治疗肺癌细胞。
Drug Des Devel Ther. 2020 Oct 23;14:4503-4510. doi: 10.2147/DDDT.S275123. eCollection 2020.
6
Preparation and evaluation of inhalable dry powder containing glucosamine-conjugated gefitinib SLNs for lung cancer therapy.制备及评价含葡萄糖胺结合型吉非替尼固体脂质纳米粒的可吸入干粉用于肺癌治疗。
Drug Dev Ind Pharm. 2020 Aug;46(8):1265-1277. doi: 10.1080/03639045.2020.1788063. Epub 2020 Jul 13.
7
Development and characterization of Brigatinib loaded solid lipid nanoparticles: In-vitro cytotoxicity against human carcinoma A549 lung cell lines.布加替尼固体脂质纳米粒的制备及特性研究：对人肺癌 A549 细胞系的体外细胞毒性。
Chem Phys Lipids. 2020 Nov;233:105003. doi: 10.1016/j.chemphyslip.2020.105003. Epub 2020 Oct 20.
8
Development of andrographolide-loaded solid lipid nanoparticles for lymphatic targeting: Formulation, optimization, characterization, in vitro, and in vivo evaluation.用于淋巴靶向的穿心莲内酯固体脂质纳米粒的研制：处方、优化、表征、体外及体内评价
Drug Deliv Transl Res. 2023 Feb;13(2):658-674. doi: 10.1007/s13346-022-01230-6. Epub 2022 Aug 17.
9
Formulation of the novel structure curcumin derivative-loaded solid lipid nanoparticles: synthesis, optimization, characterization and anti-tumor activity screening .新型结构姜黄素衍生物载固体脂质纳米粒的制剂研究：合成、优化、表征及抗肿瘤活性筛选。
Drug Deliv. 2022 Dec;29(1):2044-2057. doi: 10.1080/10717544.2022.2092235.
10
Chitosan nanoparticles as a smart nanocarrier for gefitinib for tackling lung cancer: Design of experiment and in vitro cytotoxicity study.壳聚糖纳米颗粒作为吉非替尼治疗肺癌的智能纳米载体：实验设计与体外细胞毒性研究
Int J Biol Macromol. 2023 Aug 15;246:125638. doi: 10.1016/j.ijbiomac.2023.125638. Epub 2023 Jun 30.

引用本文的文献

1
Mapping the research trends and hotspots on solid pulmonary nodules from 2000-2024: insights from bibliometric analysis.绘制2000 - 2024年实性肺结节的研究趋势与热点：文献计量分析洞察
J Thorac Dis. 2025 Jun 30;17(6):3498-3515. doi: 10.21037/jtd-24-1669. Epub 2025 Jun 11.
2
Cannabidiol-Loaded Solid Lipid Nanoparticles Ameliorate the Inhibition of Proinflammatory Cytokines and Free Radicals in an In Vitro Inflammation-Induced Cell Model.载大麻二酚固体脂质纳米粒改善体外炎症诱导细胞模型中促炎细胞因子和自由基的抑制作用。
Int J Mol Sci. 2024 Apr 26;25(9):4744. doi: 10.3390/ijms25094744.
3
Development of Gefitinib-Loaded Solid Lipid Nanoparticles for the Treatment of Breast Cancer: Physicochemical Evaluation, Stability, and Anticancer Activity in Breast Cancer (MCF-7) Cells.

本文引用的文献

1
Engineering Nano- and Microparticles as Oral Delivery Vehicles to Promote Intestinal Lymphatic Drug Transport.工程化纳米和微粒作为口服给药载体以促进肠道淋巴药物转运。
Adv Mater. 2021 Dec;33(51):e2104139. doi: 10.1002/adma.202104139. Epub 2021 Oct 1.
2
Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer.达可替尼与吉非替尼一线治疗表皮生长因子受体（EGFR）阳性晚期或转移性非小细胞肺癌的成本效益分析
Cancer Manag Res. 2021 May 28;13:4263-4270. doi: 10.2147/CMAR.S293983. eCollection 2021.
3
Pharmacokinetics and Pharmacodynamics of Curcumin-Loaded Solid Lipid Nanoparticles in the Management of Streptozotocin-Induced Diabetes Mellitus: Application of Central Composite Design.
用于治疗乳腺癌的吉非替尼载药固体脂质纳米粒的研发：物理化学评估、稳定性及对乳腺癌（MCF-7）细胞的抗癌活性
Pharmaceuticals (Basel). 2023 Nov 2;16(11):1549. doi: 10.3390/ph16111549.
4
Enhanced Codelivery of Gefitinib and Azacitidine for Treatment of Metastatic-Resistant Lung Cancer Using Biodegradable Lipid Nanoparticles.使用可生物降解脂质纳米颗粒增强吉非替尼和阿扎胞苷的联合递送用于治疗转移性耐药肺癌
Materials (Basel). 2023 Jul 30;16(15):5364. doi: 10.3390/ma16155364.
5
Hybrid Lymphatic Drug Delivery Vehicles as a New Avenue for Targeted Therapy: Lymphatic Trafficking, Applications, Challenges, and Future Horizons.混合淋巴递药系统作为靶向治疗的新途径：淋巴转运、应用、挑战与未来展望。
J Membr Biol. 2023 Jun;256(3):199-222. doi: 10.1007/s00232-023-00280-2. Epub 2023 Feb 8.
6
Optimization of Gefitinib-Loaded Nanostructured Lipid Carrier as a Biomedical Tool in the Treatment of Metastatic Lung Cancer.优化载吉非替尼的纳米结构脂质载体作为治疗转移性肺癌的生物医学工具。
Molecules. 2023 Jan 3;28(1):448. doi: 10.3390/molecules28010448.
姜黄素载固体脂质纳米粒药代动力学和药效学在链脲佐菌素诱导糖尿病治疗中的应用：中心复合设计的应用。
Assay Drug Dev Technol. 2021 May-Jun;19(4):262-279. doi: 10.1089/adt.2021.017. Epub 2021 May 17.
4
Epidemiology of lung cancer.肺癌流行病学
Contemp Oncol (Pozn). 2021;25(1):45-52. doi: 10.5114/wo.2021.103829. Epub 2021 Feb 23.
5
Adequate formulation approach for oral chemotherapy: Etoposide solubility, permeability, and overall bioavailability from cosolvent- vs. vitamin E TPGS-based delivery systems.口服化疗药物的充分制剂方法：从共溶剂-与维生素 E TPGS 为基础的给药系统的依托泊苷溶解度、渗透性和整体生物利用度。
Int J Pharm. 2021 Mar 15;597:120295. doi: 10.1016/j.ijpharm.2021.120295. Epub 2021 Jan 23.
6
Enhanced oral bioavailability of nintedanib esylate with nanostructured lipid carriers by lymphatic targeting: In vitro, cell line and in vivo evaluation.通过淋巴靶向纳米结构脂质载体提高乙磺酸盐尼达尼布的口服生物利用度：体外、细胞系及体内评价
Eur J Pharm Sci. 2021 Apr 1;159:105715. doi: 10.1016/j.ejps.2021.105715. Epub 2021 Jan 13.
7
Gefitinib encapsulation based on nano-liposomes for enhancing the curative effect of lung cancer.基于纳米脂质体的吉非替尼包封用于增强肺癌的疗效。
Cell Cycle. 2020 Dec;19(24):3581-3594. doi: 10.1080/15384101.2020.1852756. Epub 2020 Dec 10.
8
Phytochemical constituents and anticancer activities of essential oils grown in Saudi Arabia.沙特阿拉伯种植的香精油的植物化学成分及抗癌活性。
Saudi Pharm J. 2020 Nov;28(11):1474-1480. doi: 10.1016/j.jsps.2020.09.013. Epub 2020 Sep 24.
9
Nanocarriers based on vitamin E-TPGS: Design principle and molecular insights into improving the efficacy of anticancer drugs.基于维生素 E-TPGS 的纳米载体：提高抗癌药物疗效的设计原理和分子见解。
Int J Pharm. 2021 Jan 5;592:120045. doi: 10.1016/j.ijpharm.2020.120045. Epub 2020 Nov 16.
10
Lipid Drug Carriers for Cancer Therapeutics: An Insight into Lymphatic Targeting, P-gp, CYP3A4 Modulation and Bioavailability Enhancement.用于癌症治疗的脂质药物载体：对淋巴靶向、P-糖蛋白、CYP3A4调节及生物利用度提高的深入了解
Adv Pharm Bull. 2020 Sep;10(4):524-541. doi: 10.34172/apb.2020.064. Epub 2020 Aug 9.